Drugs / CAL-263
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01066611 Comparator | Jan → Apr 2010 | allergic rhinitis | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAL-263 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01066611 ↗ |
| Action | Inhibit | “PI3-kinase p110-delta subunit inhibitor” CHEMBL3545247 ↗2“PI3-kinase p110-gamma subunit inhibitor” CHEMBL3545247 ↗ “an oral inhibitor of PI3K delta” NCT01066611 ↗ |
| Route | Oral | “an oral inhibitor of PI3K delta” NCT01066611 ↗ |
| Target | PIK3CD | “PI3-kinase p110-delta subunit inhibitor” CHEMBL3545247 ↗ |
| Target | PIK3CG | “PI3-kinase p110-gamma subunit inhibitor” CHEMBL3545247 ↗ |